However, a team of researchers led by Neurexis Therapeutics Chief Scientific Officer and University of Colorado School of Medicine Professor of Pharmacology, Ulli Bayer, PhD, has discovered that LTP is driven by the structural functions of CaMKII rather than its enzymatic activity. This discovery carries immense significance as it paves the way for a novel class of inhibitors that can specifically target CaMKII’s enzymatic actions without affecting the structural functions essential for memory and learning.
According to Michael Artinger, PhD, CEO of Neurexis Therapeutics, “CaMKII is the target of our peptide inhibitor tatCN19o, which has demonstrated robust neuroprotection in multiple disease models. The results from Dr. Bayer’s lab suggest there is a significant opportunity for this therapeutic to dramatically improve the outlook for millions of people impacted by Alzheimer’s disease.”
Neurexis Therapeutics recognizes the transformative potential of these findings and their implications for advancing treatments for Alzheimer’s disease and other brain disorders, which align with its mission to develop innovative solutions that address the devastating impact of cognitive decline on patients and their families.
About Neurexis Therapeutics Diseases such as stroke, Alzheimer’s and Traumatic Brain Injury affect millions of patients each year. Neurexis’ lead neuroprotective peptide—tatCN19o—is currently in development for these and other indications. To learn more, visit neurexistherapeutics.com.
Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup (p<0.001) RADNOR, Pa., Sept. 20, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)…
Kate holds a BSc Hons degree in Industrial Microbiology from University College Dublin, an MSc in Pharma Quality Assurance/Pharma Sciences from Dublin Institute of Technology, and a Post-Grad Diploma in Manufacturing Technology (QP)/Pharma Sciences from Trinity College Dublin. This last accomplishment, gained in 2009, means Kate can act as a Qualified Person (QP) for clients in the EU. (A QP is a named individual who is responsible for ensuring that each batch of product has been manufactured in compliance with national laws and the requirements of the Marketing Authorisation, or that these have undergone comprehensive analysis if imported from elsewhere.)
On her decision to join Arriello, Kate said: “I know someone at the company who is very enthusiastic about what a great place to work Arriello is, with lots of opportunity and a strong culture. I particularly wanted to work for a boutique consultancy, where I can support the internal Quality team and continue to engage face to face with clients and provide bespoke support for their challenges, something I really appreciate.
“At Arriello I see a real opportunity to keep building the Quality function too, collaboratively with the team, in response to the evolving challenges in the market,” she continued. “Arriello has the advantage of being very dynamic – able to turn on a dime, and deliver what customers really need and want today.
“The whole pharma market is changing at speed, with an emphasis on advanced and novel/cell and gene therapies, giving rise to a whole raft of innovative new products,” Kate explained. “The challenge, though, is that there is no black and white guidance for how to ensure compliance in these novel areas, when compared to traditional drugs and decisions need to be based on risk. I have particular expertise here which I look forward to bringing to bear for Arriello’s clients.”
Kate’s career path in Ireland to date has given her particular experience of supporting rapid growth, and the design and start-up of greenfield sites. “This, coupled with my biologics background, means I’m well positioned to support pharma and biotech companies as they grow and expand,” she noted.
“I’m particularly interested in the interdependence of Regulatory and Quality,” she added. “As companies develop their strategies and processes, it’s especially important that they are able to look holistically at what they need rather than operating in silos – and Arriello’s service strategy is very much about that integrated offering.”
Welcoming Kate to the company, Anna Lukyanova, Arriello’s COO and co-founder, said: “We’re absolutely delighted. Kate is deeply experienced and well respected in fields that are extremely important to us and to our clients, and we share Kate’s excitement about the potential to build a highly positive offering that is valued by customers both now and in the future – in what is a very changeable market. Not only has Kate served as a practising QP, Principal Consultant, and qualified Lead Auditor; she is also a subject matter expert in Risk Management, New Facility Design/Start Up, Quality Control and Sterility Assurance. All of these areas are of immense value to Arriello’s clients.”
Kate, who will join Arriello in mid-September, will make her mark immediately with key speaking engagements and involvement at:
About Arriello
Arriello is a leading consultancy and solutions provider of risk management and compliance services to the pharmaceutical industry. We’ve been making the development-to-market process faster, better, and smarter since 2008.
Our global services span the product lifecycle from Clinical to post-submission Regulatory Affairs and Pharmacovigilance, Quality Assurance and Auditing, and innovative automation solutions.
Headquartered in Ireland, with operations across Europe, we consult and create solutions across the EU, North America, LATAM, CIS, MENA, Asia, and South Africa.
With our extensive global network, decades of combined experience and ISO:9001 certification, we are a trusted partner primarily to pharmaceutical and biotech companies.
Our valued clients rely on our ability to deliver, however complex their requirements, through our proven expertise, global coverage, and technology. More at www.arriello.com
Media contact: Carina Birt Sarum PR for Arriello [email protected] +44 7970 006624
With a career spanning 40+ years in software development, for the past 20 years Steve has guided companies to develop, commercialize and promote technologies that accelerate patient-centric clinical R&D. His achievements include promoting the adoption of Electronic Data Capture (EDC) at Phase Forward; the first commercialized clinical trial technology suite, at Oracle; and the first independently-validated eCOA/ePRO data capture method in decades, at uMotif.
Steve is known for his success in urging the life sciences industry to invest in clinical research technologies to gather vast amounts of high-quality data, to improve the conduct of clinical trials. He also has earned a reputation for evangelizing a focus on the patient, encouraging study sponsors to ease the patient burden by giving them appealing apps that are akin to those they use in daily life.
He is known for giving back as well, with decades of active community service including founding a non-profit to help neighbors in need; and, serving on non-profit Boards to help abused children, at-risk youth, and underserved adults.
Steve also was named to the PharmaVoice 100 in 2017, honored for being an industry change agent who opened new doors to clinical efficiency during his tenure as GM of Oracle Health Services.
“This industry is a ground-breaking one capable of changing the world through science and technology,” said Meagan Parrish, lead editor of PharmaVoice. “These honorees inspire advancements by guiding their teams, supporting their patients, and propelling their organizations’ missions forward. We are excited to recognize their contributions through this annual list.”
Steve Rosenberg said, “I’m grateful to receive this recognition a second time. For over two decades I’ve been driven to help customers speed the development of new medicines with modern technologies that make it easier to engage patients – I call them heroes – who give their time and bodies to improve healthcare for all of us.”
About uMotif
Putting patients first is in uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at www.umotif.com
MINNEAPOLIS, Sept. 19, 2023 /PRNewswire/ — Kyros, the Minnesota-based technology platform providing Substance Use Disorder (SUD) recovery services, has announced that it has raised an additional $10.5 million in funding to expand access to life-saving services. Existing investor Rally…
NEW YORK, Sept. 19, 2023 /PRNewswire/ — The “real-time location systems (RTLS) market by application (healthcare, transportation, and logistics, retail, government, and others), solution (systems and tags), and geography (North America, Europe, APAC, South America, and the Middle East…
BELIEVERS TEND TO HAVE STRONGER SELF-ESTEEM AND SELF-CONFIDENCE
80% of the Believers are highly perseverant and refuse to allow the potential for rejection or failure to deter them from taking action (compared to 59% of Non-believers).
82% believe that all problems can be resolved or their impact diminished (compared to 60% of Non-believers).
73% look for the silver lining in negative situations (compared to 54% of Non-believers).
90% believe that they deserve love, respect, and happiness (compared to 77% of Non-believers).
BELIEVERS TEND TO HAVE A STRONGER DESIRE TO IMPROVE, LEARN, AND GROW
56% regularly expand their intellectual horizons beyond their area of expertise by reading articles, watching documentaries, or listening to podcasts (compared to 44% of Non-believers).
58% try new things on a regular basis (compared to 37% of Non-believers).
55% have a bucket list that they are actively trying to accomplish (compared to 28% of Non-believers).
75% are curious to learn more about people who are different from them (compared to 65% of Non-believers).
90% view hardship is an opportunity to grow (compared to 58% of Non-believers).
69% push themselves to overcome their fears (compared to 41% of Non-believers).
BELIEVERS ARE LESS LIKELY TO STRUGGLE WITH MENTAL HEALTH ISSUES AND ENGAGE IN UNHEALTHY COPING STRATEGIES TO DEAL WITH STRESS
25% drink, smoke, or take drugs to cope with stress (compared to 46% of Non-believers).
15% have been diagnosed with an anxiety disorder (compared to 27% of Non-believers).
9% have been diagnosed with a mood disorder, such as depression or bipolar (compared to 24% of Non-believers).
HOWEVER, THE STUDY DID UNCOVER A FEW PITFALLS OF RELIGIOSITY AND SPIRITUALITY, SUCH AS THE FOLLOWING:
65% of Believers tend to passively accept negative circumstances as “destiny” or “fate” (compared to 30% of Non-believers).
26% believe that success is dependent on factors that are beyond their control (compared to 16% of Non-believers).
55% believe that most of the things that have gone wrong in their life are not their fault (compared to 50% of Non-believers).
40% see the world in black-and-white terms (compared to 20% of Non-believers).
88% believe that thinking negative thoughts can cause bad things to happen (compared to 73% of the Non-believers).
88% believe that a positive thought can cancel out a negative thought (compared to 60% of the Non-believers).
Interestingly, 51% of the religious/spiritual group said that they go out of their way to demonstrate that they are not prejudiced against members of protected groups (e.g., minorities, people with disabilities), compared to 35% of the Non-believers group. Why they feel compelled to do so is uncertain. This type of defense mechanism, known as “Reaction Formation,” is a method of redirecting a negative impulse into something positive. However, using this strategy to deal with stress or unpleasant emotions will provide temporary relief at best. The issue that is being repressed must be addressed at some point.
“Any stress management or self-improvement strategy that is effective and that doesn’t harm the user or other people is a plus in my books,” states Dr. Ilona Jerabek, president of PsychTests. “Regardless of society’s feelings about religion, those who believe in a divine being, a conscious universe, angels, or a spirit guide tend to enjoy many psychological advantages. This is because faith allows people to find comfort in chaotic times. No matter how difficult things get, it’s comforting to know that you are not alone, that someone is looking after you, and that no matter how many mistakes you make, you are still loved unconditionally. When it comes to coping with life’s ups and downs, every person has their own way. If religion or spirituality bring you joy and comfort, then follow that path. Just don’t overstep other people’s boundaries; not everyone finds comfort in religion, so allow people to find their own road to peace. And don’t forget that faith alone will not bring you happiness or success; you always need to take steps aligned with your goals or vision.”
Professional users, such as HR managers, coaches, and therapists, can request a free demo for this or other assessments from ARCH Profile’s extensive battery: http://hrtests.archprofile.com/testdrive_gen_1
About PsychTests AIM Inc. PsychTests AIM Inc. originally appeared on the internet scene in 1996. Since its inception, it has become a pre-eminent provider of psychological assessment products and services to human resource personnel, therapists and coaches, academics, researchers and a host of other professionals around the world. PsychTests AIM Inc. staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com).
“Harmonic principles” of wellbeing unveil the global population’s experiences related to balance, harmony, inner peace and contentment in life. WASHINGTON, Sept. 20, 2023 /PRNewswire/ — In a new report, Wellbeing for All: Incorporating Harmonic Principles of Wellbeing in Subjective…
Die “harmonischen Prinzipien” des Wohlbefindens beschreiben die Erfahrungen der Weltbevölkerung in Bezug auf Ausgewogenheit, Harmonie, inneren Frieden und Zufriedenheit im Leben. WASHINGTON, USA, 20. September 2023 /PRNewswire/– In einem neuen Bericht zum Thema Wohlbefinden für alle: Die…
“We are seeing a wide range of severity levels,” explained Vickie Charpie, AltaPointe’s assistant coordinator for the 988 crisis line. “From people who are calling in just having those suicidal thoughts, to people who have attempted.”
AltaPointe’s 988 crisis line team has received calls from people of all ages, including children.
“Especially with school back in session now, children may be experiencing an incident in school, being bullied or just having a bad day,” said Charpie. “We also hear from teachers and school staff who are more aware of what’s happening with our children.”
The 988 Crisis Line isn’t just for someone experiencing emotional stress. Loved ones or concerned individuals are encouraged to call, as well.
“We will work to empower them with the tools and understanding they need to help them encourage the person in crisis to reach out for help,” said Charpie.
Ultimately, the 988 crisis team works to create a safety plan for the individual in need and connect them with resources available in their community.
“In our area, we can connect them with AltaPointe’s outpatient services, our psychiatric hospitals, or our Behavioral Health Crisis Center,” explained Charpie. “And if they are outside of our counties, then we’re going to find the closest community mental health center.”
With permission, they may even do follow-up calls with high-risk callers within 24 hours to ensure the safety plan and the resources are working.
“It’s not just a one-call and done. You will connect with someone who cares and will help you through this time,” explained Charpie.
ABOUT ALTAPOINTE AltaPointe Health is an extensive mental health and family medical healthcare system in Alabama. AltaPointe clinicians provide more than 1.3 million hospital, outpatient, residential, and crisis services annually.
